vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and CyberArk Software Ltd. (CYBR). Click either name above to swap in a different company.

CyberArk Software Ltd. is the larger business by last-quarter revenue ($988.5M vs $950.5M, roughly 1.0× Astrana Health, Inc.). Astrana Health, Inc. runs the higher net margin — 0.7% vs -13.1%, a 13.8% gap on every dollar of revenue. CyberArk Software Ltd. produced more free cash flow last quarter ($144.9M vs $-6.0M).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

CyberArk Software Ltd. is an Israeli publicly traded information security company offering identity management. The company's technology is utilized primarily in the financial services, energy, retail, healthcare and government markets. CyberArk is headquartered in Petach-Tikva. The company also has offices throughout the Americas, EMEA, Asia Pacific and Japan.

ASTH vs CYBR — Head-to-Head

Bigger by revenue
CYBR
CYBR
1.0× larger
CYBR
$988.5M
$950.5M
ASTH
Higher net margin
ASTH
ASTH
13.8% more per $
ASTH
0.7%
-13.1%
CYBR
More free cash flow
CYBR
CYBR
$150.8M more FCF
CYBR
$144.9M
$-6.0M
ASTH

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ASTH
ASTH
CYBR
CYBR
Revenue
$950.5M
$988.5M
Net Profit
$6.6M
$-129.8M
Gross Margin
76.0%
Operating Margin
1.9%
-10.8%
Net Margin
0.7%
-13.1%
Revenue YoY
42.9%
Net Profit YoY
184.4%
EPS (diluted)
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
CYBR
CYBR
Q4 25
$950.5M
Q3 25
$956.0M
$988.5M
Q2 25
$654.8M
$645.6M
Q1 25
$620.4M
$317.6M
Q4 24
$665.2M
Q3 24
$478.7M
Q2 24
$486.3M
$446.3M
Q1 24
$404.4M
$221.6M
Net Profit
ASTH
ASTH
CYBR
CYBR
Q4 25
$6.6M
Q3 25
$373.0K
$-129.8M
Q2 25
$9.4M
$-79.4M
Q1 25
$6.7M
$11.5M
Q4 24
$-7.8M
Q3 24
$16.1M
Q2 24
$19.2M
$-7.5M
Q1 24
$14.8M
$5.5M
Gross Margin
ASTH
ASTH
CYBR
CYBR
Q4 25
Q3 25
76.0%
Q2 25
75.7%
Q1 25
76.0%
Q4 24
Q3 24
Q2 24
80.4%
Q1 24
80.9%
Operating Margin
ASTH
ASTH
CYBR
CYBR
Q4 25
1.9%
Q3 25
2.0%
-10.8%
Q2 25
3.1%
-8.8%
Q1 25
3.3%
-6.5%
Q4 24
0.1%
Q3 24
5.9%
Q2 24
6.2%
-6.8%
Q1 24
7.5%
-2.9%
Net Margin
ASTH
ASTH
CYBR
CYBR
Q4 25
0.7%
Q3 25
0.0%
-13.1%
Q2 25
1.4%
-12.3%
Q1 25
1.1%
3.6%
Q4 24
-1.2%
Q3 24
3.4%
Q2 24
3.9%
-1.7%
Q1 24
3.7%
2.5%
EPS (diluted)
ASTH
ASTH
CYBR
CYBR
Q4 25
$0.12
Q3 25
$0.01
Q2 25
$0.19
Q1 25
$0.14
Q4 24
$-0.14
Q3 24
$0.33
Q2 24
$0.40
Q1 24
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
CYBR
CYBR
Cash + ST InvestmentsLiquidity on hand
$429.5M
$523.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$2.3B
Total Assets
$2.2B
$4.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
CYBR
CYBR
Q4 25
$429.5M
Q3 25
$463.4M
$523.6M
Q2 25
$342.1M
$886.4M
Q1 25
$260.9M
$413.6M
Q4 24
$290.8M
Q3 24
$350.3M
Q2 24
$327.7M
$1.2B
Q1 24
$337.3M
$440.5M
Stockholders' Equity
ASTH
ASTH
CYBR
CYBR
Q4 25
$779.3M
Q3 25
$775.5M
$2.3B
Q2 25
$765.5M
$2.3B
Q1 25
$745.4M
$2.4B
Q4 24
$712.7M
Q3 24
$704.6M
Q2 24
$678.9M
$877.0M
Q1 24
$653.5M
$837.0M
Total Assets
ASTH
ASTH
CYBR
CYBR
Q4 25
$2.2B
Q3 25
$2.2B
$4.6B
Q2 25
$1.4B
$4.5B
Q1 25
$1.3B
$3.3B
Q4 24
$1.4B
Q3 24
$1.3B
Q2 24
$1.3B
$2.1B
Q1 24
$1.2B
$2.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
CYBR
CYBR
Operating Cash FlowLast quarter
$-2.9M
$153.9M
Free Cash FlowOCF − Capex
$-6.0M
$144.9M
FCF MarginFCF / Revenue
-0.6%
14.7%
Capex IntensityCapex / Revenue
0.3%
0.9%
Cash ConversionOCF / Net Profit
-0.44×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
CYBR
CYBR
Q4 25
$-2.9M
Q3 25
$10.0M
$153.9M
Q2 25
$90.9M
$103.3M
Q1 25
$16.6M
$98.5M
Q4 24
$-10.9M
Q3 24
$34.0M
Q2 24
$23.2M
Q1 24
$6.0M
$68.6M
Free Cash Flow
ASTH
ASTH
CYBR
CYBR
Q4 25
$-6.0M
Q3 25
$7.4M
$144.9M
Q2 25
$89.5M
$98.8M
Q1 25
$13.6M
$96.8M
Q4 24
$-13.5M
Q3 24
$31.7M
Q2 24
$20.4M
Q1 24
$5.6M
$66.8M
FCF Margin
ASTH
ASTH
CYBR
CYBR
Q4 25
-0.6%
Q3 25
0.8%
14.7%
Q2 25
13.7%
15.3%
Q1 25
2.2%
30.5%
Q4 24
-2.0%
Q3 24
6.6%
Q2 24
4.2%
Q1 24
1.4%
30.1%
Capex Intensity
ASTH
ASTH
CYBR
CYBR
Q4 25
0.3%
Q3 25
0.3%
0.9%
Q2 25
0.2%
0.7%
Q1 25
0.5%
0.5%
Q4 24
0.4%
Q3 24
0.5%
Q2 24
0.6%
Q1 24
0.1%
0.8%
Cash Conversion
ASTH
ASTH
CYBR
CYBR
Q4 25
-0.44×
Q3 25
26.69×
Q2 25
9.65×
Q1 25
2.48×
8.60×
Q4 24
Q3 24
2.11×
Q2 24
1.21×
Q1 24
0.40×
12.55×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

CYBR
CYBR

Subscription$794.5M80%
Maintenance, Professional Services and other$194.0M20%

Related Comparisons